Overview

Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, open-label study, designed to evaluate the effect of renal disease on the pharmacokinetics of BAL4815 (active isavuconazole moiety) relative to the pharmacokinetics in healthy subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborator:
Basilea Pharmaceutica International Ltd
Treatments:
Isavuconazole